Choice of first-line therapy in metastatic melanoma

Cancer. 2019 Mar 1;125(5):666-669. doi: 10.1002/cncr.31774. Epub 2019 Jan 29.

Authors

Geoffrey T Gibney¹, Michael B Atkins¹

Affiliation

¹ Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC.

PMID: 30695110
DOI: 10.1002/cncr.31774

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / genetics
Clinical Trials as Topic
Humans
Melanoma / drug therapy*
Melanoma / genetics
Melanoma / immunology
Molecular Targeted Therapy
Neoplasm Metastasis
Precision Medicine
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Survival Analysis
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
Protein Kinase Inhibitors